A call for harmonized surveillance recommendations in cardio-oncology.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

1. 'Patients are left not knowing': Trastuzumab (Herceptin) cardiac risk information and management in HER2-positive breast cancer-a qualitative study of patient experience.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
   Article
2. Personalized Trastuzumab-Induced Cardiac Dysfunction Risk Stratification and Surveillance.JACC. CardioOncology · 2025
   Article

Corrections and comments

• Commented on by
  Harmonizing the cardiovascular care of adult patients with cancer.2023
• Comment on
  2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS).2022

Authors and funding

3 authors at 3 institutions in 2 countries.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as